Outcome of patients maintaining CR for more than 1 year after relapse without DLI
| UPN . | Age at time of relapse, y . | Sex, recipient/donor . | Type of donor . | Status at allo-SCT . | Year of allo-SCT . | Time of relapse after allo-SCT, mo . | Tumor lesion at relapse . | IS at relapse . | GVHD at relapse . | GVHD after withdrawing IS (type of cGVHD) . | Response to withdrawing IS . | Salvage treatment . | Response to salvage treatment . | OS after relapse, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 57 | F/M | R-BM | PIF | 2005 | 4.6 | CNS | None | Absent | PD | IT only | CR | 63.9+ | |
| 11 | 55 | F/F | R-BM | PR | 2000 | 14.3 | Bone | None | Absent | PD | RT | CR | 118.6+ | |
| 12 | 63 | F/F | UR-CB | PIF | 2007 | 45.9 | Lymph nodes | None | Absent | PD | RT | CR | 19.0+ | |
| 13 | 50 | F/M | R-BM | PR | 2005 | 0.9 | Lymph nodes | CsA | Absent | Emergence (limited) | CR | Not done | - | 46.7+ |
| UPN . | Age at time of relapse, y . | Sex, recipient/donor . | Type of donor . | Status at allo-SCT . | Year of allo-SCT . | Time of relapse after allo-SCT, mo . | Tumor lesion at relapse . | IS at relapse . | GVHD at relapse . | GVHD after withdrawing IS (type of cGVHD) . | Response to withdrawing IS . | Salvage treatment . | Response to salvage treatment . | OS after relapse, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 57 | F/M | R-BM | PIF | 2005 | 4.6 | CNS | None | Absent | PD | IT only | CR | 63.9+ | |
| 11 | 55 | F/F | R-BM | PR | 2000 | 14.3 | Bone | None | Absent | PD | RT | CR | 118.6+ | |
| 12 | 63 | F/F | UR-CB | PIF | 2007 | 45.9 | Lymph nodes | None | Absent | PD | RT | CR | 19.0+ | |
| 13 | 50 | F/M | R-BM | PR | 2005 | 0.9 | Lymph nodes | CsA | Absent | Emergence (limited) | CR | Not done | - | 46.7+ |
R-BM indicates related BM; UR-CB, unrelated cord blood; PIF, primary induction failure; CsA, cyclosporine A; IT, intrathecal injection of cytarabine, methotrexate and prednisone; and RT, local radiation therapy.